Exchange: NASDAQ·Updated 07:30 PM EST

CSBR News

News
all
press releases
Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?
CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.
Zacks
Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?
CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.
Zacks
More News
On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
Champions Oncology (NASDAQ:CSBR) released third-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
On Thursday, Champions Oncology (NASDAQ:CSBR) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Zacks
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
Zacks
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Zacks

Advertisement|Remove ads.